Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure

[1]  A. Eggermont,et al.  One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases , 2004, Annals of surgery.

[2]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Eggermont,et al.  Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion , 2000, British Journal of Cancer.

[4]  H. Polk,et al.  Post-Perfusion Recurrent Melanoma , 1999, Annals of Surgical Oncology.

[5]  A. Eggermont,et al.  Absence of Severe Systemic Toxicity After Leakage-Controlled Isolated Limb Perfusion With Tumor Necrosis Factor-α and Melphalan , 1999, Annals of Surgical Oncology.

[6]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[7]  S. Libutti,et al.  Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics , 1997, Cancer.

[8]  P. Kam,et al.  Frequency and duration of remission after isolated limb perfusion for melanoma. , 1997, Archives of surgery.

[9]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[10]  A. Eggermont,et al.  Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. , 1996, Journal of the American College of Surgeons.

[11]  P. Schlag,et al.  Treatment of melanoma in-transit metastases confined to the limb , 1996, Acta Chirurgica Austriaca.

[12]  A. Eggermont,et al.  Rationale for using TNFα and chemotherapy in regional therapy of melanoma , 1994 .

[13]  A. Eggermont,et al.  Systemic leakage during isolated limb perfusion for melanoma , 1993, The British journal of surgery.

[14]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[15]  A. Eggermont,et al.  Fifty Tumor Necrosis Factor–Based Isolated Limb Perfusions for Limb Salvage in Patients Older Than 75 Years With Limb-Threatening Soft Tissue Sarcomas and Other Extremity Tumors , 2003, Annals of surgical oncology.

[16]  A. Eggermont,et al.  Systemic Toxicity and Cytokine/Acute Phase Protein Levels in Patients After Isolated Limb Perfusion With Tumor Necrosis Factor-a Complicated by High Leakage , 2000, Annals of Surgical Oncology.

[17]  A. Feldman,et al.  Management of Extremity Recurrences After Complete Responses to Isolated Limb Perfusion in Patients With Melanoma , 1999, Annals of Surgical Oncology.

[18]  C. Wiltschke,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[21]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .